Compare MAC & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAC | PTCT |
|---|---|---|
| Founded | 1964 | 1998 |
| Country | United States | United States |
| Employees | 2845 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.7B |
| IPO Year | 1994 | 2006 |
| Metric | MAC | PTCT |
|---|---|---|
| Price | $21.59 | $70.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | $20.50 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 2.1M | 750.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | 11.36 | ★ 264.48 |
| EPS | N/A | ★ 7.78 |
| Revenue | ★ $1,013,983,000.00 | $264,734,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.70 | $19.02 |
| P/E Ratio | ★ N/A | $9.29 |
| Revenue Growth | 10.43 | ★ 36.19 |
| 52 Week Low | $14.16 | $35.95 |
| 52 Week High | $22.56 | $87.50 |
| Indicator | MAC | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 65.04 | 52.14 |
| Support Level | $17.84 | $69.81 |
| Resistance Level | N/A | $72.44 |
| Average True Range (ATR) | 0.48 | 2.24 |
| MACD | 0.17 | 0.26 |
| Stochastic Oscillator | 72.71 | 49.33 |
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and seven other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $867 sales per square foot over the 12 months ended in September 2025.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.